A novel four‐gene signature predicts immunotherapy response of patients with different cancers

Background Immune checkpoint blockade (ICB) therapy has demonstrated favorable clinical efficacy, particularly for advanced or difficult‐to‐treat cancer types. However, this therapy is ineffective for many patients displaying lack of immune response or resistance to ICB. This study aimed to establish a novel four‐gene signature (CD8A, CD8B, TCF7, and LEF1) to provide a prognostic immunotherapy biomarker for different cancers. Methods Transcriptome profiles and clinical data were obtained from The Cancer Genome Atlas database. Multivariate Cox regression analysis was used to establish a four‐gene signature. The R package estimate was used to obtain the immune score for every patient. Results Risk scores of the novel four‐gene signature could effectively divided all patients into high‐ and low‐risk groups, with distinct outcomes. The immune score calculated via the estimate package demonstrated that the four‐gene signature was significantly associated with the immune infiltration level. Furthermore, the four‐gene signature could predict the response to atezolizumab immunotherapy in patients with metastatic urothelial cancer. Conclusions The novel four‐gene signature developed in this study is a good prognostic biomarker, as it could identify many kinds of patients with cancer who are likely to respond to and benefit from immunotherapy. Multivariate Cox regression analysis was used to establish a novel four‐gene signature, which was significantly associated with the immune infiltration level. The four‐genesignature could predict the response to atezolizumab immunotherapy in patients withmetastatic urothelial cancer. The novel four‐gene signature developed in this study isa good prognostic biomarker, as it could identify many kinds of patients with cancerwho are likely to respond to and benefit from immunotherapy.